Novo's Wegovy Secures Accelerated FDA Approval for MASH
Novo Nordisk's Wegovy (semaglutide) is now FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH) with liver scarring, a significant advancement for this serious condition.
/ 5 items
#NVO↓
Eli Lilly's highly anticipated obesity pill yields modest results.
Lilly's new oral GLP-1, orforglipron, shows 11-12.4% weight loss in late-stage trial, short of Zepbound and Wegovy. Easier to produce and distribute than injectables, it targets wider patient access. FDA submission this year.
Novo Nordisk Navigates US Market Headwinds & Leadership Shift
Novo Nordisk faces slowing growth, fierce competition from Eli Lilly and copycats in the US, prompting a CEO change and strategic refocus.
Trump Admin Eyes Major GLP-1 Weight Loss Drug Coverage
The Trump administration is considering a five-year pilot program for Medicare & Medicaid to cover costly GLP-1 weight-loss drugs like Wegovy & Zepbound for millions, a significant policy shift.
Novo Nordisk Lowers 2025 Outlook, Names New CEO
Novo Nordisk cut its 2025 sales and profit forecast due to slower US Wegovy & Ozempic sales, hit by competition and compounded GLP-1s. Maziar Mike Doustdar is the new CEO.